Advertisement
News
Subscribe to MDT Magazine News

FDA Consumer Health Information - FDA's MedWatch Safety Alerts: May 2011

June 28, 2011 10:36 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., June 28, 2011 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has recently issued safety alerts about a number of products, including: (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) birth control pills that may increase the risk of blood...

TOPICS:

New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients

June 28, 2011 10:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, June 28, 2011 /- Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart...

TOPICS:

Aeris Therapeutics names new CFO Carter

June 28, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Aeris Therapeutics LLC, a Woburn-based drug developer focused on treatments for emphysema and other advanced lung diseases, has appointed a new chief financial officer in Charles R. Carter.

TOPICS:
Advertisement

Allied Minds names Oxford's Amirana to head life sciences group

June 28, 2011 9:39 am | by Mass High Tech: The Journal of New England Technology | Comments

Early-stage technology investment firm Allied Minds Inc. today named Omar Amirana, M.D., as managing director of life sciences. Dr. Amirana is a recognized life sciences leader and investor with more than twenty years of experience in the life sciences industry.

Patients Treated with Sunitinib and Sorafenib Respond to Flu Vaccine

June 28, 2011 9:34 am | by AACR | Comments

Tweet   • Flu vaccine could be used to test immune response. • Patients presented with metastatic renal cell cancer. • Implications beyond quality of life and patient management. PHILADELPHIA - Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests...

TOPICS:

Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team

June 28, 2011 8:37 am | by Bio-Medicine.Org | Comments

MINNEAPOLIS, June 28, 2011 /- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and...

TOPICS:

Hologic to Release Third Quarter Fiscal 2011 Operating Results on Monday, August 1, 2011

June 28, 2011 8:36 am | by Bio-Medicine.Org | Comments

BEDFORD, Mass., June 28, 2011 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced plans to...

TOPICS:

Bill Gates-backed startup Nimbus Discovery closes $24M funding

June 28, 2011 7:40 am | by Mass High Tech: The Journal of New England Technology | Comments

Nimbus Discovery LLC, a computational technology-based drug discovery firm in Cambridge, has closed a $24 million Series A funding round, co-led by Atlas Venture, SR One and Lilly Ventures. Microsoft Corp. founder Bill Gates returned to participate in funding as well.

Advertisement

Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform

June 28, 2011 7:38 am | by Bio-Medicine.Org | Comments

RESTON, Va., June 28, 2011 /- The Mirixa Corporation and the Canadian Association of Chain Drug Stores (CACDS) are pleased to announce that MirixaPro(SM), a Web-based clinical platform that supports and documents standardized, pharmacy-based patient care service delivery, will be deployed...

TOPICS:

Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men

June 28, 2011 7:38 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, June 28, 2011 /- Eli Lilly and Company (NYSE: LLY ) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution CIII, when applied to the underarm, met the primary study objective...

TOPICS:

Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease

June 28, 2011 7:38 am | by Bio-Medicine.Org | Comments

HOBOKEN, N.J., June 28, 2011 /- Octapharma USA recently hosted an International Physician Advisory Board in New York City, bringing together medical experts from around the world who have extensive experience internationally with taking care of patients with von Willebrand's Disease...

TOPICS:

IBM Study Identifies New Generation of Connected Health Devices

June 28, 2011 7:37 am | by IBM | Comments

Consumers have a growing appetite for health and wellness devices, and this represents a burgeoning market opportunity for device manufacturers that has barely been tapped, according to a study from IBM (NYSE: IBM). The company also unveiled a list of possible wellness device innovations...

TOPICS:

Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit

June 28, 2011 7:35 am | by Bio-Medicine.Org | Comments

MADISON, Wis., June 28, 2011 /- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011, Judge Nathaniel M. Gorton allowed the defendants' motion to dismiss the putative federal...

TOPICS:

Rcadia Medical Imaging Awarded Four U.S. Patents Covering Technology for Automated Analysis of Coronary CT Angiography

June 28, 2011 7:35 am | by Bio-Medicine.Org | Comments

NEWTON, Mass., June 28, 2011 /- Rcadia Medical Imaging today announced that the company has been granted four patents by the U.S. Patent and Trademark Office covering technology for its COR Analyzer® System.  The COR Analyzer performs fully automatic analysis of Coronary CT...

TOPICS:

DaTscanâ„¢ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes

June 28, 2011 7:35 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., June 28, 2011 /- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading